Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.30 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101458 | 0.92 | FFAR4 (0.33) | FFAR4RETEGFRITKWDR5 | |
| SCHEMBL22101383 | 0.90 | PIK3CB (0.30) | — | |
| SCHEMBL22101491 | 0.87 | ALDH1A1 (0.33) | — | |
| SCHEMBL22101877 | 0.82 | KDM4E (0.38) | — | |
| SCHEMBL22101361 | 0.81 | KDM4E (0.34) | — | |
| SCHEMBL22101452 | 0.81 | MAPT (0.33) | — | |
| SCHEMBL22101490 | 0.79 | MAPT (0.35) | — | |
| SCHEMBL22393591 | 0.79 | MAPT (0.33) | FFAR4 | |
| SCHEMBL22101539 | 0.77 | FFAR4 (0.35) | FFAR4 | |
| SCHEMBL22101472 | 0.76 | FFAR4 (0.32) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | FFAR4 270/4885RET 381/4885EGFR 352/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | FFAR4 270/4885RET 381/4885EGFR 352/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | FFAR4 270/4885RET 381/4885EGFR 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.